Wave Life Reacquires WVE-006, Eyes FDA Review for 200k Patients
Wave Life regained full rights to WVE-006 for alpha-1 antitrypsin deficiency from GSK, targeting 200,000 U.S. and European patients, and plans an FDA accelerated approval meeting with feedback due mid-2026. Under the agreement, it is eligible for $2.8 billion in milestones plus tiered royalties and has cash into Q3 2028.
1. Rights Reacquisition
On February 2, Wave Life regained full global rights to WVE-006, its RNA-based therapy for alpha-1 antitrypsin deficiency, from GSK. This disorder lacks approved treatments and affects approximately 200,000 individuals across the U.S. and Europe.
2. Regulatory Strategy
Wave Life plans to meet with the U.S. Food and Drug Administration to pursue an accelerated approval pathway for WVE-006, with regulatory feedback expected by mid-2026. The company aims to leverage this pathway to fast-track clinical development and market access.
3. Financial and Collaboration Terms
Under the amended collaboration, Wave Life is eligible to receive up to $2.8 billion in initiation, development, launch and commercialization milestones plus tiered royalties on sales. The company reports a cash runway sufficient to fund operations into the third quarter of 2028.
4. Analyst Outlook
Wedbush analyst Yun Zhong maintained a Buy rating on Wave Life with a $33 price target, reflecting confidence in WVE-006’s potential and the company’s strategic positioning in the rare disease market.